Ignite Creation Date:
2024-05-06 @ 7:30 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06030648
Status:
SUSPENDED
Last Update Posted:
2023-09-11
First Post:
2023-08-31
Brief Title:
MT2022-01 MSCs for ALD
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Study Overview
Official Title:
Intravenous Administration of Mesenchymal Stem Cells IV-MSC for the Treatment of Cerebral Adrenoleukodystrophy cALD
Status:
SUSPENDED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Awaiting supplies
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-institution study to evaluate the use of intravenously administered allogeneic 3rd party mesenchymal stem cells IV-MSC in patients with active cerebral adrenoleukodystrophy CALD as a bridge to hematopoietic stem cell transplant or gene therapy or in patients who are too advanced for gene therapy or HSCT The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None